KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Invested Capital (2019 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Return on Invested Capital for 7 consecutive years, with 0.09% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Invested Capital rose 26.0% to 0.09% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.09%, a 26.0% increase, with the full-year FY2025 number at 0.08%, up 25.0% from a year prior.
  • Return on Invested Capital was 0.09% for Q4 2025 at Xenon Pharmaceuticals, up from 0.56% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.04% in Q1 2022 to a low of 0.56% in Q3 2025.
  • A 5-year average of 0.24% and a median of 0.25% in 2021 define the central range for Return on Invested Capital.
  • Peak YoY movement for Return on Invested Capital: fell -26bps in 2021, then increased 26bps in 2025.
  • Xenon Pharmaceuticals' Return on Invested Capital stood at 0.05% in 2021, then crashed by -229bps to 0.18% in 2022, then crashed by -56bps to 0.27% in 2023, then fell by -29bps to 0.35% in 2024, then skyrocketed by 74bps to 0.09% in 2025.
  • Per Business Quant, the three most recent readings for XENE's Return on Invested Capital are 0.09% (Q4 2025), 0.56% (Q3 2025), and 0.47% (Q2 2025).